Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LALIT ANEJA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1386989820
CMS profile
1717328
Location
NORTH VENICE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,965.62

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,840.50 135
Education $125.12 4

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LALIT ANEJA

NPI 1386989820 · CMS profile ID 1717328

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NORTH VENICE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386989820?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386989820?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386989820?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1386989820?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $2,965.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–139 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $10.9004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049214631 CMS
Janssen Biotech, Inc. $16.3903/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988182305 CMS
Celgene Corporation $19.7903/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015895823 CMS
Daiichi Sankyo Inc. $28.4503/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006339435 CMS
Merck Sharp & Dohme LLC $22.1603/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048832475 CMS
Novartis Pharmaceuticals Corporation $24.7803/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991690005 CMS
E.R. Squibb & Sons, L.L.C. $20.2503/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015895801 CMS
Epizyme, Inc. $21.2103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 981307197 CMS
Alexion Pharmaceuticals, Inc. $14.0703/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017008683 CMS
Novartis Pharmaceuticals Corporation $20.3203/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991689997 CMS
Merck Sharp & Dohme LLC $24.5503/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048597139 CMS
E.R. Squibb & Sons, L.L.C. $20.3702/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015895789 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.3702/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000501277 CMS
G1 Therapeutics, Inc. $20.6602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059919321 CMS
Sumitomo Pharma America, Inc. $17.0302/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031022109 CMS
Daiichi Sankyo Inc. $28.4602/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006393707 CMS
GENZYME CORPORATION $17.7102/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050284581 CMS
Novartis Pharmaceuticals Corporation $20.5002/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991689993 CMS
GENZYME CORPORATION $16.8302/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050284577 CMS
GlaxoSmithKline, LLC. $48.4402/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002007281 CMS
JAZZ PHARMACEUTICALS INC. $38.0402/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058395129 CMS
Daiichi Sankyo Inc. $23.4702/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006383825 CMS
Deciphera Pharmaceuticals Inc. $25.2902/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053715823 CMS
Kite Pharma, Inc. $21.0902/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025266985 CMS
Celgene Corporation $26.4202/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015895761 CMS
Astellas Pharma US Inc $21.2602/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033894633 CMS
Lilly USA, LLC $14.3502/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031774657 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.7801/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055334689 CMS
Novartis Pharmaceuticals Corporation $16.4601/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991689989 CMS
Lilly USA, LLC $25.4301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031774653 CMS
Eisai Inc. $15.2901/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023319149 CMS
Eisai Inc. $19.0801/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023319151 CMS
E.R. Squibb & Sons, L.L.C. $19.2601/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015895757 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.9601/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996979205 CMS
Merck Sharp & Dohme LLC $10.8501/11/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048596813 CMS
Merck Sharp & Dohme LLC $10.9401/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048596817 CMS
Merck Sharp & Dohme LLC $10.8501/11/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048829385 CMS
Amgen Inc. $18.4301/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019996373 CMS
Merck Sharp & Dohme LLC $20.9901/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048829387 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,652.85 110
PY2020 $654.22 44
PY2021 $3,123.15 35
PY2022 $2,426.83 128
PY2023 $2,965.62 139
PY2024 $3,377.85 156
PY2025 $3,337.26 144

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $166,698.43 23
PY2024 Principal investigator $62,293.78 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) No dispute reported 06/30/2026 1185538765
Principal investigator 1 Janssen Research & Development, LLC $11,719.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329744
Principal investigator 1 Janssen Research & Development, LLC $3,818.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329695
Principal investigator 1 Genentech, Inc. $5,000.00 12/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
KRAS combo ph1b No dispute reported 06/30/2026 1211649968
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327225
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327522
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328641
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329288
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $361.69 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223288119
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328715
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327952
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 09/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329733
Principal investigator 1 Janssen Research & Development, LLC $2,912.67 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327071
Principal investigator 1 Genentech, Inc. $4,063.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211649070
Principal investigator 1 Janssen Research & Development, LLC $7,330.00 07/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329200
Principal investigator 1 Genentech, Inc. $596.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211649065
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $596.00 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223280760
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,285.00 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185538767
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185538761
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,967.07 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185538757
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,750.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185538769
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,600.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185538759
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,900.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185538763